Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $58.55

Shares of Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the company, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $58.55.

A number of analysts recently issued reports on the company. Wolfe Research assumed coverage on Tempus AI in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target for the company. Guggenheim initiated coverage on Tempus AI in a report on Monday, December 9th. They issued a "buy" rating and a $74.00 price target for the company. Piper Sandler restated a "neutral" rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Needham & Company LLC restated a "buy" rating and set a $56.00 target price on shares of Tempus AI in a report on Tuesday, January 14th. Finally, Bank of America upped their target price on Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a report on Friday, December 13th.

Tempus AI Price Performance

Shares of NASDAQ TEM traded down $8.63 during trading hours on Wednesday, reaching $68.09. The stock had a trading volume of 14,840,563 shares, compared to its average volume of 14,399,394. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The business's fifty day moving average price is $49.75 and its two-hundred day moving average price is $51.44. Tempus AI has a 52-week low of $22.89 and a 52-week high of $91.45.

Insider Activity

In related news, Director David R. Epstein sold 620 shares of the company's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total value of $25,922.20. Following the transaction, the director now directly owns 27,894 shares of the company's stock, valued at $1,166,248.14. This represents a 2.17 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the company's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,583,467 shares of company stock worth $130,542,311.

Hedge Funds Weigh In On Tempus AI

Hedge funds have recently made changes to their positions in the company. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI in the 3rd quarter valued at $30,000. Operose Advisors LLC acquired a new position in shares of Tempus AI in the 4th quarter valued at $25,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI during the 4th quarter worth about $34,000. Prestige Wealth Management Group LLC grew its position in Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after purchasing an additional 965 shares during the period. Finally, NewEdge Advisors LLC acquired a new stake in Tempus AI during the 4th quarter worth about $49,000. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.